Cyrille Pichot's questions to Global Cord Blood (CORBF) leadership • Q4 2021
Question
Cyrille Pichot from Altimeo posed questions regarding the company's acquisition strategy outside of China, its plans for the Qilu stake, and its potential interest in a secondary Hong Kong listing due to new regulations and U.S. delisting risks.
Answer
CFO Bing Chen confirmed the company is actively exploring acquisition opportunities both within and outside of China to expand its service portfolio and mitigate geographical and regulatory risks. He highlighted uncertainties from the new Biosecurity Law and a pause on new cord blood banking licenses as drivers for this strategy. Regarding a Hong Kong listing, Mr. Chen noted he was monitoring the U.S. PCAOB situation but was not aware of the specific listing rule changes mentioned.